You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR OMONTYS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Omontys

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00097747 ↗	Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers	Completed	Affymax	Phase 1	2004-08-01	The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
NCT00109291 ↗	Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease	Terminated	Affymax	Phase 2	2005-03-01	To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
NCT00228436 ↗	Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients	Completed	Affymax	Phase 2	2005-09-01	The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis stimulating agent (ESA) treatment.
NCT00228449 ↗	Peginesatide for Anemia in Chronic Hemodialysis Patients	Completed	Affymax	Phase 2	2005-07-01	The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Omontys

Condition Name

Chart
Table

Condition Name for Omontys
Intervention	Trials
Anemia	17
Chronic Kidney Disease	14
Chronic Renal Failure	13
Cancer	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Omontys
Intervention	Trials
Anemia	15
Renal Insufficiency, Chronic	14
Renal Insufficiency	14
Kidney Failure, Chronic	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Omontys

Trials by Country

Map
Table

Trials by Country for Omontys
Location	Trials
United States	160
United Kingdom	10
Poland	5
Romania	4
Bulgaria	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Omontys
Location	Trials
Texas	10
California	10
New York	8
Florida	8
Virginia	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Omontys

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Omontys
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	11
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Omontys
Clinical Trial Phase	Trials
Completed	14
Terminated	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omontys

Sponsor Name

Chart
Table

Sponsor Name for Omontys
Sponsor	Trials
Affymax	16
Takeda	9
Amgen	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Omontys
Sponsor	Trials
Industry	26
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.